DNASE1L3
EmergingDNASE1L3 deficiency (inherited or via autoantibody) impairs DNA clearance, a proposed mechanism generating lupus autoantibodies.
This enzyme normally cleans up DNA from dead cells. When it's missing (from birth) or blocked (by an antibody against it), DNA lingers around longer than it should, which is now understood to be one of the ways lupus and its related antibodies can develop.
DNASE1L3 encodes an enzyme that normally clears DNA released from dying cells; both inherited deficiency and acquired autoantibodies against this enzyme are implicated in lupus pathogenesis.
Inherited null mutations in DNASE1L3 cause a rare, severe early-onset monogenic form of lupus, while acquired neutralizing autoantibodies against DNASE1L3 itself (found in over half of sporadic lupus nephritis patients in one study) are a more common mechanism impairing the same DNA-clearance pathway.
Genetic testing identifies the rare monogenic form in early-onset, severe lupus presentations; anti-DNASE1L3 antibody testing remains largely a research tool rather than a standardized clinical assay at this time.
This connects directly to the anti-dsDNA antibody discussion from earlier in this biomarker set: impaired DNA clearance from either mechanism is a proposed pathway generating the anti-dsDNA antibodies characteristic of lupus, offering a mechanistic explanation rather than a distinct treatment pathway at present.
Connects mechanistically to the anti-dsDNA antibody discussion, offering insight into how these antibodies may arise.
- General rheumatology/genetics reference literature on DNASE1L3 in monogenic and sporadic lupus pathogenesis.